ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Adv…

2024 ESMO Annual Meeting Insights Hub

B. Monk

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

2024 ASCO® Annual Meeting Insights Hub

M. Raza Mirza

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Gynecologic Oncology Updates: Expert Perspective on Key Trial Findin…

Yale Cancer Center

E. Ratner

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagn…

2024 ESMO Annual Meeting Insights Hub

B. Monk

ASCO® 2024 Summary: "Timing of Debulking Surgery in Advanced Endomet…

2024 ASCO® Annual Meeting Insights Hub

A. Karam

ESMO 2024 Insights: PRIMA Trial - Newly Diagnosed Advanced Ovarian C…

ecancer

A. González-Martín

Cancer Screening Molecular Tools

Fengting Yan

Year in Review 2024 - Ovarian Cancer

Oncology 2024 Year in Review

E. Crane

Management of Recurrent Ovarian Clear Cell Carcinoma

David Tan

Addressing the Critical Gaps in Relapsed Ovarian Cancer Management

Michael Birrer

Defining Platinum Resistance in Ovarian Cancer

Michael Birrer

2024 Updates in Ovarian Cancer

Total Health

T. Tillmanns

UChicago Medicine Best of ASCO® 2024: Options for Recurrent Platinum…

UChicago Medicine Annual Practice Updates in Hematology and Oncology

H. Cun

Updates on Maintenance Therapy in Advanced Ovarian Cancer

Paul DiSilvestro

Antibody Drug Conjugates in Gynecologic Oncology: From Bench to Beds…

UCLA Health

G. Konecny

Precision Oncology in the Management of Ovarian Cancer

Miami Cancer Institute Precision Oncology Symposium

D. Dizon

Ovarian Cancer Patient Experience With Niraparib: Assessing QoL Data…

Erin Crane